TRUFF — Red Light Holland Corp.
—
OTC ·
Unknown ·
Unknown ·
CIK 1836747 ·
Last close
$0.01
Market Cap
$8.35M
52W High
$0.04
52W Low
$0.00
ADV30
133,490
Next earnings
2026-11-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 186,070 | 169,737 | -1,402,319 | -1,866,594 | 21,861,244 | 2,597,788 | 3,823,877 |
| Mar 2026 | 875,322 | 458,573 | -787,508 | -2,527,999 | 14,569,516 | 8,471,343 | 3,349,190 |
| Dec 2025 | 1,264,798 | 357,920 | -1,197,457 | -1,378,899 | 18,199,952 | 9,237,626 | 3,583,397 |
| Sep 2025 | 754,084 | 327,294 | -996,236 | -1,166,695 | 19,018,028 | 10,226,236 | 3,405,796 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-2,421,528
Investing CF
$-1,226,324
Financing CF
$-766,029
CapEx
$-1,226,324
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$0.00
As of
2026-09-06
Balance + Analyst (yfinance extras)
Retained Earnings
$-48,301,671
Inventory
$846,129
Receivables
$478,514
ST Investments
$581,578
EBIT TTM
$-7,112,186
Pretax Income TTM
$-7,170,661
Interest Exp TTM
$58,475
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,828,412
EBITDA
$-4,329,649
Free Cash Flow
$-376,339
Enterprise Value
$4,990,637
Total Cash
$8,129,682
Total Debt
$1,445,991
Shares Out
614,124,756
Trailing EPS
$0.00
Book Value
$0.02
ROE
-41.3%
ROA
-13.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 4,195,369 | -4,124,766 | -6,101,998 | 14,569,516 | 3,349,190 | 11,966,082 | -2,421,528 |
| Mar 2025 | 4,944,378 | -4,210,297 | -4,042,202 | 21,221,392 | 3,871,805 | 17,352,380 | -1,482,702 |
| Mar 2024 | 4,751,981 | -6,187,065 | -7,627,281 | 24,083,960 | 3,821,658 | 20,070,195 | -3,228,133 |
| Mar 2023 | 3,949,667 | -4,952,810 | -5,398,167 | 30,143,283 | 3,800,453 | 26,064,213 | -4,386,694 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MILIF | Military Metals Corp. | $8.32M | $0.10 | — |
| APMCF | MORIEN RESOURCES CORP. | $8.43M | $0.14 | — |
| FRECF | Frequency Exchange Corp. | $8.25M | $0.14 | — |
| MARPS | MARINE PETROLEUM TRUST | $8.50M | $4.25 | — |
| LCTC | Lifeloc Technologies, Inc | $8.51M | $3.09 | — |
News headlines (Yahoo Finance, 1h cache)
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to UCSF for Phase 1 Trial of Psilocybin in Healthy Older Adults with Low Well-Being
2026-11-17 13:20 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to King's College London
2026-11-09 12:31 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Southern California for the Expanded Mindfulness Assisted Psychedelic Therapy Trial
2026-11-03 13:02 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing
2026-11-02 12:37 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder
2026-10-28 12:00 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depressio
2026-10-16 12:55 · Yahoo
Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor
2026-10-14 12:34 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorde
2026-10-08 12:19 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Calgary for Phase 2 Trial of Psilocybin-Assisted Therapy for PTSD in Survivors of Intimate Partner Viol
2026-09-29 11:53 · Yahoo
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Expands Supply Agreement with the University of Chieti-Pescara for PEX010 in the TEMPO Clinical Trial of Psilocybin for Treatment-Resista
2026-09-25 12:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.